Adma Biologics shares closed up 2.01% at $9.13, outpacing the S&P 500's 0.17% gain for the session. The infectious disease drug developer is expected to report quarterly EPS of $0.19, up 18.75% from the prior-year quarter, on revenue of $139.8 million, up 4.16% year over year. For the full year, the Zacks Consensus Estimates project earnings of $0.78 per share and revenue of $536.82 million, representing changes of +30% and +5.22%, respectively, from the prior year. The stock holds a Zacks Rank of #3 (Hold) and trades at a Forward P/E ratio of 11.52, a discount to its industry's average Forward P/E of 23.81.
ADMA Biologics IncAdma Biologics shares rose after earnings beat expectations, with EPS projected up 18.75% year over year.
